Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals — Investor Presentation (April 2017)

34 slides from Opiant Pharmaceuticals's investor presentation, Apr 19, 2017

  1. Slide 1: Focused on Addiction

    FOCUSED ON ADDICTION Investor Presentation April 2017 OTCQB: OPNT

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement 2 This presentation contains ‘forward - looking statements’ within the meaning of Section of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These forward - looking statements relate to future events or our future fi

  3. Slide 3: OPNT: Focused on Addiction

    3 OPNT: Focused on Addiction A Commercial - Stage Specialty Pharma Company Focused on Addiction Leveraging expertise, technology and a record of success to address the leading sources of addiction • Opioids • Alcohol • Food

  4. Slide 4: Lead Programs

    4 Lead Programs Indication Product Candidate / Regulatory Pathway Preclinical Phase 1 Phase II Phase III NDA FDA Approval Partner Opioid Overdose NARCAN® Nasal Spray 505(b)(2) Alcohol Dependence OPNT002 Opioid Antagonist Nasal Spray / 505(b)(2) Eating Disorders OPNT001 Opioid Antagonist Nasal Spray

  5. Slide 5: Management team

    Arvind Agrawal MSc EVP, Medical Affairs Extensive addiction and CNS drug development experience 5 Dr. Roger Crystal MD MRCS MBA Chief Executive Officer Kevin Pollack, JD MBA Chief Financial Officer Mark Ellison, Ph.D. EVP Development, Manufacturing and Quality Dr. Phil Skolnick Ph.D   D.Sc  hon

  6. Slide 6: Opiant's mission: leading biopharma focused on addictions and eating disorders

    Opiant’s mission: to become a leading biopharma focused on addictions and eating disorders Replicate recent success Enter Larger Markets Invest long term Deliver on first program • Deliver more programs, with the potential for filing NDAs within 3 - 4 years at relatively low cost, primarily using na

  7. Slide 7: Addressing Addiction

    Addressing Addiction @ Opiant

  8. Slide 8: Addiction has evolved as a disease, now more acceptable to treat with pharmacotherapy

    8 Addiction has evolved as a disease, and now more acceptable to treat with pharmacotherapy The Past: Addicts as “junkies”; abstinence the only solution The Present: Addiction now recognized as a brain disease; abstinence no longer viewed as the only acceptable outcome The Future: Promising pharmaco

  9. Slide 9: Addiction now represents an attractive commercial opportunity

    Addiction now represents an attractive commercial opportunity 9 Strong sales from existing products • Suboxone sales > $1B • 27% growth in Vivitrol sales expected for 2017 - $250M Significant unmet need & increased government funding • Only 1 in 9 addicts receive appropriate treatment • Problem grow

  10. Slide 10: Addictions driven by the brain's reward center, blocked by opioid antagonists

    10 Addictions are driven by the brain’s reward center releasing dopamine which can be blocked by opioid antagonists • Dopamine controls the brain’s reward and pleasure centers • Opioids flood the brain with dopamine, leading to misuse and abuse The Addicted Brain • Opioid antagonists bind to opiate

  11. Slide 11: OPNT001 displaces carfentanyl from the brain's breathing and reward centers

    Opiant’s OPNT001 opioid antagonist displaces the opioid carfentanyl from the brain’s breathing and reward centers 11 Prior to OPNT001 2 time points after administration of OPNT001

  12. Slide 12: Opioid antagonists validated as therapeutics with excellent safety profile

    12 Opioid antagonists have been validated as therapeutics with an excellent safety profile

  13. Slide 13: NARCAN Nasal Spray

    NARCAN® Nasal Spray @ Opiant pe 13

  14. Slide 14: Opioid addiction and overdose: a significant public health crisis

    14 Opioid addiction and overdose: A significant public health crisis Source: Centers for Disease Control and Prevention • Opioid overdose deaths have increased dramatically since 2000 • The majority of opioid overdose deaths are accidental following legitimate use • Approximately 33,000 overdose dea

  15. Slide 15: Naloxone saves lives if given quickly

    15 Naloxone saves lives if given quickly However: only trained personnel able to deliver injectable form, which delays lifesaving treatment Timing is Everything: Understanding the Urgency to Respond Quickly Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid

  16. Slide 16: NARCAN Nasal Spray is the only FDA-approved nasal naloxone

    16 NARCAN® Nasal Spray is the only FDA - approved nasal naloxone for reversal of opioid overdose • Developed by Opiant • 2 doses now FDA approved, 2mg and 4mg • Higher dose increasingly important for overdose caused by fentanyl and other synthetics • Licensed to Adapt Pharma in 2014 for $55+ million

  17. Slide 17: NARCAN Nasal Spray: rapid absorption with higher blood levels

    17 NARCAN® Nasal Spray: Rapid absorption with higher blood levels compared to 0.4mg injectable naloxone Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0

  18. Slide 18: NARCAN Nasal Spray: easiest to use, needle free, among the least expensive

    18 NARCAN® Nasal Spray – Easiest to use, needle free and among the least expensive Injectable Naloxone Autoinjectors Improvised Nasal Kits NARCAN® Nasal Spray • Only suitable for trained personnel • Requires prep time • Requires a needle • Expensive • Not needle free - requires an injection • Only s

  19. Slide 19: Potential $2B addressable market in U.S.

    19 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. *Opiant estimate of average selling price ** Co - prescribing starting to happen – mandatory in Vermont for high risk patients First Responders 1M patients with opioid use disorder taking methadone, suboxo

  20. Slide 20: Beyond Overdose: Addressing Chronic Treatment of Addictions

    Beyond Overdose … .Addressing Chronic Treatment of Addictions 20

  21. Slide 21: Leveraging NARCAN success to address larger, broader addiction markets

    Opiant is leveraging NARCAN® success to address larger, broader addiction markets 12M 1.5M Opioid Overdose ~33k deaths per year Alcohol Use Disorder ~17 million Eating Disorders ~20 million Opioid Use Disorder ~2.4 million ACUTE CHRONIC 21

  22. Slide 22: Alcohol Use Disorder: 500k patients prescribed ~$360M of mostly generic medication

    Alcohol Use Disorder (AUD): 500k patients prescribed ~$360M of mostly generic medication at treatment centers 22 • Of the 17M patients that meet the diagnostic criteria for an AUD, only 500k patients receive mostly generic pharmacotherapy, mostly at dedicated treatment centers • Approximately $360M

  23. Slide 23: Existing pharmacotherapies for Alcohol Use Disorder have limitations

    23 OPNT Existing Pharmacotherapies Criteria OPNT002 * Acamprosate Disulfiram Naltrexone HCl (Oral: ReVia ® / Generics) Naltrexone HCl (Injection: Vivitrol ®) “As - needed” use basis ✔ ✘ ✘ Can be used this way, but not current US practice ✘ Well - tolerated ✔ ✔ ✘ ✘ ✔ Safety ✔ − − ✔ ✔ Craving impact p

  24. Slide 24: OPNT002 will be a differentiated product

    Combining targeted dosing with a harm reduction endpoint, OPNT002 will be a differentiated product 24 • Patients will take the nasal spray when they have the urge to drink • Attractive, targeted “as needed” dosing approach – improved tolerability, compliance and patient acceptability over daily dosi

  25. Slide 25: FDA feedback supportive of OPNT002 development plan

    25 FDA feedback supportive of OPNT002 development plan alongside attractive commercial opportunity • Phase 1 data highly encouraging • Further clinical studies planned for 2H 2017 • 505(b)(2) regulatory pathway confirmed – increased likelihood and speed for FDA approval • Potential to self - commerc

  26. Slide 26: OPNT001 for Eating Disorders

    OPNT001 for Eating Disorders 26

  27. Slide 27: Eating disorders affect millions with only one drug approved in each indication

    Eating disorders affect millions with only one drug approved in each indication 27 Bulimia Nervosa • Bingeing and purging • Severe complications if untreated • Compulsive bingeing has features in common with addictions • Fluoxetine only approved drug Binge Eating Disorder • Most common eating disord

  28. Slide 28: OPNT001 Phase 2 trial design for Bulimia Nervosa

    OPNT001 Phase 2 trial design for Bulimia Nervosa 28 • Randomized, double blind, placebo controlled study of 4mg IN OPNT001 in patients suffering from Bulimia Nervosa in the UK • 80 patients • Primary endpoint – reduction in binge eating days • Expected duration – 12 months (further guidance once pat

  29. Slide 29: OPNT001 shows promise for Binge Eating Disorder

    164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 OPNT001 shows promise for Binge Eating Disorder 29 Proof of concept study (Helsinki) • (n=127) in patients with BED, Randomized, double blind, placebo controlled study • OPNT001 dose 2mg before e

  30. Slide 30: Corporate

    Corporate @ Opiant pe 30

  31. Slide 31: Extensive IP coverage

    31 Extensive IP coverage: Four Orange Book listed patents and several more IP filings across many indications Co - Packaging/Co - Provision Spray Plume Geometry Single Pre - Primed Device Formulation & Dose PET Data Receptor Occupancy Clinical Data Absorption Blood PK Data Methods Treat Overdose

  32. Slide 32: Corporate/Clinical Milestones

    32 Corporate/Clinical Milestones Enhance corporate governance through establishment of Board committees (1Q 2017) Initiate of Phase 2 trial of OPNT001 in Bulimia Nervosa (2Q 2017) Uplist to a major stock exchange Strengthen management team through appointment of a CSO (1Q 2017) Initiate OPNT 002 Alc

  33. Slide 33: OPNT: Investment Highlights

    33 OPNT: Investment Highlights Record of commercialization in addiction, where others have failed High value pipeline, clinical and regulatory success in developing nasally - delivered opioid antagonists Significant competitive advantages and strong IP Strong partnerships and strengthened balance sh

  34. Slide 34: Focused on Addiction

    FOCUSED ON ADDICTION www.opiant.com

Opiant Pharmaceuticals — Investor Presentation (April 2017) on 6ix